Adenosquamous carcinoma of the lung

From Libre Pathology
Revision as of 14:48, 6 April 2023 by Michael (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Adenosquamous carcinoma of the lung, also lung adenosquamous carcinoma, is a rare epithelial derived malignancy of the lung with features of both adenocarcinoma and squamous cell carcinoma.

Adenosquamous carcinoma of the lung
Diagnosis in short

Adenosquamous carcinoma of lung. H&E stain.
LM DDx squamous cell carcinoma of the lung, adenocarcinoma of the lung
Site lung - see lung tumours
Prevalence rare
Clin. DDx other lung tumours

It is grouped with the non-small cell lung cancers.

General

Microscopic

Features:[3][4]

  1. Adenocarcinoma component (>=10% of tumour ‡).
  2. Squamous cell carcinoma component (>=10% of tumour ‡).

Note:

  • ‡ Criteria used by individual pathologists may vary and/or may not be uniformly applied.[3]

DDx:

Images

  • ASC - intermed. mag. (WC)

  • ASC - intermed. mag. (WC)

  • ASC - high mag. (WC)

  • ASC - very high mag. (WC)

www

Sign out

Biopsy - possible adenosquamous carcinoma

Left Upper Lobe of Lung, Core Biopsy:
     - NONSMALL CELL CARCINOMA, FAVOUR ADENOCARCINOMA, CANNOT EXCLUDE ADENOSQUAMOUS CARCINOMA.

Comment:
The tumour stains as follow:
POSITIVE: TTF-1, CK5/6 (focal), p63, napsin A.
NEGATIVE: (none).

The positive staining (TTF-1 and napsin A versus CK5/6 and p63) appears to be in different tumour cells.  

The case was reviewed internally and there is agreement on the above interpretation.

Note:

  • Cases should not be signed as adenosquamous carcinoma on biopsy, due to the percentage requirements (>=10% for both components) - see microscopic section.

See also

References

  1. ↑ Song, Z.; Lin, B.; Shao, L.; Zhang, Y. (Sep 2013). "Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.". J Chin Med Assoc 76 (9): 481-5. doi:10.1016/j.jcma.2013.05.007. PMID 23769878.
  2. ↑ Iwanaga, K.; Sueoka-Aragane, N.; Nakamura, T.; Mori, D.; Kimura, S. (2012). "The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.". Intern Med 51 (19): 2771-4. PMID 23037472.
  3. ↑ 3.0 3.1 Rao, N. (Jul 2014). "Adenosquamous carcinoma.". Semin Diagn Pathol 31 (4): 271-7. doi:10.1053/j.semdp.2014.06.004. PMID 25002356.
  4. ↑ Vassella E, Langsch S, Dettmer MS, Schlup C, Neuenschwander M, Frattini M, Gugger M, Schäfer SC (September 2015). "Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?". Oncotarget 6 (27): 23905–16. doi:10.18632/oncotarget.4163. PMC 4695160. PMID 26068980. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695160/.
Retrieved from "https://librepathology.org/w/index.php?title=Adenosquamous_carcinoma_of_the_lung&oldid=52279"